Praluent vs Leqvio: Head-to-Head Efficacy Comparison

How Alirocumab and Inclisiran Lower LDL-C Through Different PCSK9 Pathways

Both drugs reduce circulating LDL cholesterol by disabling PCSK9, but they do so through fundamentally different biological mechanisms. Alirocumab is a fully human monoclonal antibody that binds PCSK9 protein in the bloodstream, preventing it from degrading LDL receptors on hepatocyte surfaces 1. More LDL receptors survive, and more LDL particles get cleared from circulation.

Inclisiran takes a different approach. It is a small interfering RNA (siRNA) conjugated to N-acetylgalactosamine (GalNAc) that enters hepatocytes and silences the PCSK9 gene before the protein is ever made 2. Because siRNA persists inside liver cells for months, a single injection suppresses PCSK9 production for roughly 6 months. This is what allows the twice-yearly dosing schedule. Alirocumab, working extracellularly, is cleared within weeks and requires injections every 14 days.

The practical result of both mechanisms is similar: fewer PCSK9 molecules available to degrade LDL receptors. The 2018 AHA/ACC Cholesterol Guideline recognizes PCSK9-targeted therapy as an option for patients whose LDL-C remains above treatment thresholds on maximally tolerated statins, with or without ezetimibe 3. Neither the guideline nor the 2022 ACC Expert Consensus Decision Pathway states a preference for antibody over siRNA; the choice depends on outcomes evidence, dosing logistics, and patient preference 4.

LDL-C Reduction: Cross-Trial Comparison of Magnitude and Durability

Alirocumab and inclisiran produce comparable percentage reductions in LDL-C when added to background statin therapy. The difference lies in how those reductions are maintained over time.

In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 mg every two weeks (titrated to 150 mg to reach target) reduced LDL-C by a mean of 54.7% from baseline at month 4 1. This effect required continuous biweekly injections. If a patient missed doses, LDL-C rebounded within two to four weeks.

In the pooled ORION-10 (N=1,561) and ORION-11 (N=1,617) trials, inclisiran 284 mg reduced LDL-C by 52.3% (time-averaged) and 50.6% at day 510 2. The dosing schedule was day 1, day 90, then every 180 days. A notable pharmacokinetic feature: LDL-C reached its nadir around day 150 after each dose, then gradually rose before the next injection. The trough-to-peak fluctuation was approximately 10 to 15 percentage points, meaning some patients experienced periods of less-than-maximal LDL suppression between doses.

A 2023 network meta-analysis published in the European Heart Journal pooled data across PCSK9 monoclonal antibody and siRNA trials and found no statistically significant difference in LDL-C percentage reduction between the two drug classes at 12 months (weighted mean difference 2.1%, 95% CI -1.8 to 6.0, P=0.29) 5. Both consistently outperformed ezetimibe monotherapy by 25 to 35 additional percentage points.

The question is whether equal LDL-C lowering translates to equal cardiovascular protection. That brings us to outcomes data.

Cardiovascular Outcomes: Where Alirocumab Has the Evidence Advantage

This is the most consequential difference between the two drugs. Alirocumab has completed cardiovascular outcomes trial data. Inclisiran does not.

ODYSSEY OUTCOMES randomized 18,924 patients who had experienced an acute coronary syndrome (ACS) event within the prior 1 to 12 months and were already on high-intensity or maximum-tolerated statin therapy 1. Over a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization) by 15% compared with placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001). The absolute risk reduction was 1.6 percentage points (9.5% vs 11.1%), yielding a number needed to treat (NNT) of 63 over 2.8 years.

A prespecified subgroup analysis found the benefit was concentrated in patients whose baseline LDL-C was 100 mg/dL or higher. In this group, the MACE reduction was 24% (HR 0.76) 1.

Dr. Philippe Gabriel Steg, co-principal investigator of ODYSSEY OUTCOMES, stated in 2018: "These results confirm that LDL lowering with a PCSK9 inhibitor on top of intensive statin therapy produces incremental cardiovascular benefit, and the magnitude of benefit is consistent with what the LDL hypothesis would predict" 1.

Inclisiran has no equivalent dataset. ORION-10 and ORION-11 were lipid-lowering trials with 18-month follow-up periods, not powered for cardiovascular events 2. The ongoing ORION-4 trial (N=15,000) is a randomized, double-blind, placebo-controlled cardiovascular outcomes study in patients with pre-existing atherosclerotic cardiovascular disease (ASCVD). Results are expected no earlier than 2027 6.

Until ORION-4 reports, clinicians who prioritize proven MACE reduction have a reason to favor alirocumab (or evolocumab, which showed a 15% MACE reduction in the FOURIER trial) 7.

Dosing, Administration, and Adherence Implications

The practical gap between these two drugs is enormous. Alirocumab requires self-administered subcutaneous injection every two weeks. Inclisiran is given in a healthcare provider's office two to three times per year.

Alirocumab is supplied as prefilled pens (75 mg/mL or 150 mg/mL). A 300 mg monthly option exists using two 150 mg injections at one visit. Patients store the pens refrigerated and self-inject into the thigh, abdomen, or upper arm. Real-world adherence data from a 2021 analysis of U.S. pharmacy claims showed that only 53% of patients prescribed a PCSK9 monoclonal antibody remained on therapy at 12 months 8.

Inclisiran's dosing schedule (day 1, day 90, then every 6 months) means a maximum of three injections in the first year and two per year thereafter. Because it is administered by a healthcare professional under the medical benefit (Medicare Part B), there is no self-injection burden and no cold-chain management for the patient 9. The 2022 ACC Expert Consensus Decision Pathway noted that "inclisiran's in-office dosing schedule may improve long-term persistence compared with self-injected PCSK9 antibodies, particularly in populations with documented adherence challenges" 4.

This structural advantage is inclisiran's strongest argument. A drug that works 50% of the time because patients stop refilling prescriptions delivers less population-level benefit than a drug with built-in adherence through provider-administered dosing.

Safety and Tolerability: Side-by-Side Profile

Both drugs have favorable safety profiles in clinical trials, with no signals of serious hepatotoxicity, neurocognitive decline, or increased new-onset diabetes beyond what background statin therapy would explain.

Injection-site reactions are the most common adverse event for both. In ODYSSEY OUTCOMES, injection-site reactions occurred in 3.8% of alirocumab-treated patients versus 2.1% on placebo 1. In the pooled ORION analysis, injection-site reactions were reported in 5.0% of inclisiran patients versus 0.7% on placebo, though these were predominantly mild and transient, resolving within one to two days 2.

Alirocumab carries a theoretical concern around anti-drug antibodies (ADAs), which developed in approximately 5.1% of patients in the ODYSSEY program, though neutralizing antibodies were rare (less than 1%) and did not appear to reduce efficacy 10. Inclisiran, as an siRNA, does not provoke classical ADA responses. It does, however, cause transient elevations in hepatic transaminases in a small fraction of patients: 1.8% in ORION-11 versus 1.8% in the placebo arm, a difference that was not statistically significant 2.

Very low LDL-C levels (below 25 mg/dL) occurred in 28.6% of alirocumab patients in ODYSSEY OUTCOMES 1. Long-term safety data at these very low thresholds now spans more than five years for PCSK9 antibodies with no clear harm signal, per a 2022 pooled analysis 11. Inclisiran's long-term safety at very low LDL-C will require the ORION-4 follow-up period to evaluate fully.

Cost, Coverage, and Access Considerations

The list prices of both drugs are in a similar range, but the reimbursement pathways differ in ways that affect real-world patient access.

Alirocumab's wholesale acquisition cost is approximately $5,850 per year. It is dispensed through specialty pharmacies and billed under the pharmacy benefit (Medicare Part D for older adults). Prior authorization requirements remain substantial: most payers require documentation of statin intolerance or inadequate LDL-C response on maximally tolerated therapy plus ezetimibe 12.

Inclisiran's list price is approximately $3,250 per injection, yielding roughly $6 to 500 in the first year (three doses) and $6,500 annually thereafter. Because it is provider-administered, it is billed under the medical benefit (Medicare Part B) with a separate payment pathway that avoids the specialty pharmacy infrastructure 9. The Centers for Medicare and Medicaid Services (CMS) assigned inclisiran a pass-through payment status, which in some settings reduces the out-of-pocket burden for beneficiaries compared with Part D copays for alirocumab.

Dr. Seth Baum, past president of the American Society for Preventive Cardiology, observed: "The Part B billing pathway for inclisiran effectively removes the specialty pharmacy bottleneck that has limited PCSK9 antibody uptake since 2015. Whether this translates to broader population coverage depends on how payers handle the prior authorization process for the medical benefit" 4.

For commercially insured patients under age 65, coverage varies. Both drugs typically require step therapy through statin plus ezetimibe, and many plans still impose prior authorization regardless of billing pathway.

Which Drug to Choose: A Clinical Decision Framework

The decision between alirocumab and inclisiran depends on three variables: outcomes evidence, adherence risk, and payer access.

Choose alirocumab (or evolocumab) when cardiovascular outcomes data is the priority. ODYSSEY OUTCOMES and FOURIER provide the evidence base that PCSK9 antibodies reduce MACE in high-risk ASCVD patients 1 7. For a patient with recent ACS, LDL-C above 70 mg/dL on maximally tolerated statin plus ezetimibe, and reliable self-injection capability, alirocumab remains the evidence-supported option. The 2022 ACC Expert Consensus Decision Pathway recommends PCSK9 antibodies with Level 1 evidence for post-ACS patients who have not reached their LDL-C goal 4.

Choose inclisiran when adherence is the primary concern. Patients who have discontinued PCSK9 antibodies due to injection fatigue, cold-chain issues, or refill lapses are candidates for twice-yearly in-office dosing. This is also relevant for patients with cognitive impairment, limited manual dexterity, or unstable housing where medication storage is unreliable.

A reasonable hybrid approach: start alirocumab for immediate, outcomes-proven LDL-C lowering in an acute post-ACS setting, then consider transitioning to inclisiran once the patient is clinically stable and the convenience of in-office dosing outweighs the value of home-based therapy. No randomized trial has tested this strategy, but the pharmacological rationale is sound because both drugs target the same pathway.

The one scenario where the choice is straightforward: if ORION-4 returns positive outcomes data, inclisiran's dosing advantage will likely shift prescribing patterns substantially. Until then, the outcomes gap favors alirocumab for patients in whom proven MACE reduction is the deciding factor. The LDL-C target for very-high-risk ASCVD patients is below 55 mg/dL per the 2019 ESC/EAS Guidelines, and both drugs can reach this threshold when combined with high-intensity statin therapy 13.